$MRNA Moderna Pops 15%  after received a “crucial” FDA approval for phase 2 trials of its vaccine candidate. 'early summer' start for phase 3 COVID-19 vaccine trial  $DJ_F $DJIA $SPX $ES_F @CNBC @MARKETS #CORONAVIRUS https://t.co/onluTudgMl